Last reviewed · How we verify
NCT05612789
Improve Outcomes for Older Allogeneic Transplant Recipients
NA trial testing Exercise Program (Cohort A Prehab) in Allogeneic Transplantation in 72 participants. Currently enrolling.
1 June 2030
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 15 February 2023 |
| Primary completion | 1 June 2030 |
| Estimated completion | 1 June 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Exercise Program (Cohort A Prehab)
- Exercise Program (Cohort B Rehab)
Conditions studied
- Allogeneic Transplantation — all drugs for Allogeneic Transplantation →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
60 and older, any sex, with Allogeneic Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tailoring Therapy in Older Adults With Hematologic Malignancies.
Mangan BL, DuMontier C, Hopkins JO, Abel GA, et al · · 2024 · cited 4× · PMID 38788182 · DOI 10.1200/edbk_432220
Verify or expand the search:
- PubMed search for NCT05612789
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allogeneic Transplantation
Currently open trials in the same condition.
- NCT06450353 — Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation · recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05612789 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05612789.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing